Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 4:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–23 of 23 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Sildenafil study group Clear all
Terminated Phase 4 Interventional Results available

To Assess The Efficacy and Safety Of Oral Sildenafil in the Treatment of Pulmonary Arterial Hypertension.

NCT00430716
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Sildenafil citrate
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
15
States / cities
Phoenix, Arizona • Augusta, Georgia • Decatur, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2020 · Synced Sep 5, 2026, 4:13 PM EDT
Completed Phase 3 Interventional Results available

A Long Term Extension Study Evaluating Safety Of Sildenafil Citrate When Used To Treat Pulmonary Arterial Hypertension (PAH) In Children

NCT00159874
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Sildenafil citrate
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
1 Year to 17 Years
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
11
States / cities
Palo Alto, California • Stanford, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2021 · Synced Sep 5, 2026, 4:13 PM EDT
Completed Phase 4 Interventional

A Study Of The Safety and Efficacy Of Viagra In Men With Erectile Dysfunction Who Do Not Self Identify.

NCT00343200
View directory record Official record
Conditions
Impotence
Interventions
Placebo, Viagra (sildenafil citrate)
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
30 Years and older · Male only
Enrollment
371 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
48
States / cities
Huntsville, Alabama • Mesa, Arizona • Phoenix, Arizona + 42 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2021 · Synced Sep 5, 2026, 4:13 PM EDT
Recruiting Phase 1 Interventional

IMProving DRug Dosing and Outcomes for Single VEntricle Patients With Fontan Associated Liver Disease

NCT06324396
View directory record Official record
Conditions
Fontan Circulation
Interventions
Sildenafil 10mg oral tablet (participants <20kg), or 20mg oral tablet (participants ≥20kg), Pravastatin 20 mg oral tablet (ages <13 years), or 40 mg oral tablet (≥14 years)
Drug
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
8 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 1, 2026 · Synced Sep 5, 2026, 4:13 PM EDT
Completed Phase 3 Interventional Results available

The Efficacy and Safety of Sildenafil Citrate Used in Combination With Intravenous Epoprostenol in PAH

NCT00159861
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Sildenafil citrate
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
16 Years and older
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
33
States / cities
La Jolla, California • Los Angeles, California • San Diego, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2021 · Synced Sep 5, 2026, 4:13 PM EDT
Completed Phase 3 Interventional Results available

Pharmacokinetic Effects of QTI571 on Sildenafil and Bosentan in Pulmonary Arterial Hypertension Participants

NCT01392469
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Imatinib, Sildenafil, Bosentan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
3
States / cities
Tampa, Florida • Weston, Florida • Mineola, New York
Source: ClinicalTrials.gov public record
Updated Jun 20, 2021 · Synced Sep 5, 2026, 4:13 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

Cerebrovascular Reactivity Assessed With fNIRS as a Biomarker of TCVI After Acute Traumatic Brain Injury in Military

NCT04058132
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Sildenafil Citrate 50Mg Tab, functional Near-infrared Spectroscopy (fNIRS), Carbon Dioxide (CO2) 5%, Neuropsychological Assessments, Gadolinium contrast infusion, Blood sample collection for research purposes, Structural brain Magnetic Resonance Imaging (MRI
Drug · Device · Other + 1 more
Lead sponsor
Uniformed Services University of the Health Sciences
Federal
Eligibility
18 Years to 55 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 27, 2024 · Synced Sep 5, 2026, 4:13 PM EDT
Completed No phase listed Observational Results available

Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies

NCT01266265
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
inhaled prostacyclin, prostacyclin, subcutaneous and intravenous prostacyclin, oral ERA, oral PDE5 inhibitors
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
Not listed
Enrollment
1,333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
88
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2016 · Synced Sep 5, 2026, 4:13 PM EDT
Terminated Phase 2 Interventional Results available

Sildenafil Therapy for Pulmonary Hypertension and Sickle Cell Disease

NCT00492531
View directory record Official record
Conditions
Sickle Cell Disease, Pulmonary Hypertension
Interventions
Sildenafil, Placebo
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
12 Years to 70 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
8
States / cities
Oakland, California • Denver, Colorado • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2016 · Synced Sep 5, 2026, 4:13 PM EDT
Completed Phase 3 Interventional Results available

A Study To Evaluate Safety And Efficacy Of IV Sildenafil In The Treatment Of Neonates With Persistent Pulmonary Hypertension Of The Newborn

NCT01720524
View directory record Official record
Conditions
Pulmonary Hypertension, Familial Persistent, of the Newborn
Interventions
placebo, iv sildenafil
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
0 Days to 4 Days
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
20
States / cities
Little Rock, Arkansas • Sacramento, California • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2021 · Synced Sep 5, 2026, 4:13 PM EDT
Terminated Phase 2 Interventional Results available

A Research Study To Assess The Effectiveness And Safety Of Different Doses Of Oral PF-00489791 In The Treatment Of Adult Patients With Pulmonary Arterial Hypertension

NCT00853112
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
PF-00489791, placebo, sildenafil
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
8
States / cities
Phoenix, Arizona • Gainesville, Florida • Omaha, Nebraska + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2017 · Synced Sep 5, 2026, 4:13 PM EDT
Not yet recruiting Early Phase 1 Interventional

Asciminib With or Without Sildenafil for Brain Tumors

NCT07039760
View directory record Official record
Conditions
Brain Tumor
Interventions
Asciminib, Sildenafil, Surgical resection or biopsy
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 39 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 5, 2026, 4:13 PM EDT
Completed Phase 3 Interventional Results available

A Randomized, Double-Blind, Placebo-Controlled Study of Sildenafil in Children With Pulmonary Arterial Hypertension.

NCT00159913
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Children
Interventions
Sildenafil citrate, Placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
1 Year to 17 Years
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
10
States / cities
Palo Alto, California • Stanford, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Sep 5, 2026, 4:13 PM EDT
Completed Phase 3 Interventional

Mono vs. Dual Therapy for Pediatric Pulmonary Arterial Hypertension

NCT04039464
View directory record Official record
Conditions
Pediatric Pulmonary Hypertension
Interventions
Mono-Therapy with Sildenafil, Duo-Therapy with Sildenafil + Bosentan
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
3 Months to 18 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
10
States / cities
Aurora, Colorado • St. Petersburg, Florida • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Sep 5, 2026, 4:13 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Nintedanib Co-administered With Sildenafil in Idiopathic Pulmonary Fibrosis Patients With Advanced Lung Function Impairment

NCT02802345
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Nintedanib, Placebo, Sildenafil
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
17
States / cities
Birmingham, Alabama • Stamford, Connecticut • Jacksonville, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2019 · Synced Sep 5, 2026, 4:13 PM EDT
Completed Phase 2 Interventional Results available

Safety of Sildenafil in Premature Infants

NCT03142568
View directory record Official record
Conditions
Bronchopulmonary Dysplasia
Interventions
Sildenafil, Placebo
Drug · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
7 Days to 28 Days
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
14
States / cities
Little Rock, Arkansas • Jacksonville, Florida • Chicago, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Sep 5, 2026, 4:13 PM EDT
Completed Phase 3 Interventional Results available

Concomitant Use of PriLigy in Men Treated for Erectile Dysfunction

NCT01063855
View directory record Official record
Conditions
Erectile Dysfunction, Sexual Dysfunction
Interventions
Placebo, Dapoxetine, PDE5I (phosphodiesterase-5 inhibitor)
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older · Male only
Enrollment
495 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
19
States / cities
Decatur, Alabama • Huntsville, Alabama • Englewood, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Sep 5, 2026, 4:13 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Hypoxic Pulmonary Vasoconstriction Pilot Study

NCT03733470
View directory record Official record
Conditions
Emphysema
Interventions
Sildenafil study group
Drug
Lead sponsor
Eric A. Hoffman
Other
Eligibility
30 Years to 60 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Sep 30, 2019 · Synced Sep 5, 2026, 4:13 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Non-invasive Measurement of Cerebrovascular Reactivity After Traumatic Brain Injury

NCT02990078
View directory record Official record
Conditions
TBI
Interventions
Sildenafil citrate, Functional Near Infared Spectroscopy, Hypercapnia Challenge
Drug · Device · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 12, 2022 · Synced Sep 5, 2026, 4:13 PM EDT
Withdrawn Phase 4 Interventional

Pulmonary Hypertension Secondary to Idiopathic Pulmonary Fibrosis And Treatment With Sildenafil

NCT00625079
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, Pulmonary Hypertension
Interventions
sildenafil
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 30, 2018 · Synced Sep 5, 2026, 4:13 PM EDT
Completed Phase 4 Interventional

A Multicenter, Randomized, Parallel Group, Double-Blind, Placebo Controlled, Flexible Dose Escalation Study To Evaluate Sexual And Relationship Satisfaction In The Female Partner Of Men With Erectile Dysfunction Treated With Sildenafil Citrate

NCT00644631
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
sildenafil, placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
21 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
31
States / cities
Huntsville, Alabama • Little Rock, Arkansas • Beverly Hills, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2021 · Synced Sep 5, 2026, 4:13 PM EDT
Terminated Not applicable Interventional Results available

Improving Erectile Function and Quality of Life After Prostate Cancer Treatment

NCT01996852
View directory record Official record
Conditions
Prostate Cancer, Erectile Dysfunction Following Radical Prostatectomy, Erectile Dysfunction Following Simple Prostatectomy, Erectile Dysfunction
Interventions
Cognitive-behavioral Meetings, sildenafil citrate, Vacuum Constriction Device
Behavioral · Drug · Device
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
21 Years and older · Male only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 9, 2019 · Synced Sep 5, 2026, 4:13 PM EDT
Completed Phase 1 Interventional

Growth Hormone or Sildenafil as Therapies for Fatigue in Mild- Traumatic-brain-injury (MTBI)

NCT02114775
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Growth Hormone, Sildenafil, Placebo
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 60 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 4, 2018 · Synced Sep 5, 2026, 4:13 PM EDT